v3.26.1
Fair Value Measurements - Contingent Consideration and Contingent Founder Shares (Details)
 3 Months Ended 6 Months Ended
Apr. 27, 2023
$ / shares
shares
Jun. 30, 2026
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
Feb. 28, 2025
$ / shares
Class of Stock [Line Items]              
Threshold increase in Episodic Migraine Contingent Consideration Shares 152,998            
Number of Chronic Migraine Contingent Consideration Shares by increase in Episodic Migraine Contingent Consideration Shares 0            
Number of Contingent Consideration Shares to be issued upon Threshold Increase in Episodic Migraine Contingent Consideration Shares 0            
Reduction in number of Chronic Migraine Contingent Consideration Shares 13,996            
Minimum number of Chronic Migraine Contingent Consideration Shares after Reduction 0            
Income related to the change in fair value of contingent consideration | $   $ (10,000) $ 16,000 $ (15,000) $ (3,472,000)    
Contingent consideration liability | $   $ 27,000   $ 27,000   $ 42,000  
Common stock, par value | $ / shares   $ 0.0001   $ 0.0001   $ 0.0001 $ 0.0001
Maximum              
Class of Stock [Line Items]              
Number of additional shares to be issued 222,653            
Reduction in Episodic Migraine Contingent Consideration Shares 13,996            
Founder Shares              
Class of Stock [Line Items]              
Percentage of shares unvested and subject to the restrictions and forfeiture provisions 50.00%            
Number of founder shares subject to vesting and forfeiture conditions 47,921            
Number of founder shares forfeited     13,980        
Percentage of shares not subject to restrictions and forfeiture provisions 50.00%            
Number of common stock issued on conversion 95,842            
Founder Shares | Priveterra              
Class of Stock [Line Items]              
Common stock, par value | $ / shares $ 0.0001            
Share Conversion Ratio 1            
Migraine Phase 3 Contingent Founder Shares              
Class of Stock [Line Items]              
Number of founder shares subject to vesting and forfeiture conditions 20,141            
Migraine Phase 3 Contingent Founder Shares | Upon the achievement of the conditions for the issuance of the CD BLA Contingent Consideration Shares on or prior to the CD BLA Outside Date              
Class of Stock [Line Items]              
Number of founder shares subject to vesting and forfeiture conditions 13,890            
CD BLA Contingent Founder Shares              
Class of Stock [Line Items]              
Number of additional shares to be issued 55,659            
Number of founder shares subject to vesting and forfeiture conditions 55,659            
Episodic/Chronic Migraine Contingent Founder Shares              
Class of Stock [Line Items]              
Number of additional shares to be issued 152,998            
Number of common shares become due and payable 27,992            
Episodic/Chronic Migraine Contingent Founder Shares | Maximum              
Class of Stock [Line Items]              
Reduction in Episodic Migraine Contingent Consideration Shares 27,992            
Episodic Migraine Contingent Consideration Shares              
Class of Stock [Line Items]              
Number of additional shares to be issued 55,659            
Chronic Migraine Contingent Consideration Shares              
Class of Stock [Line Items]              
Number of additional shares to be issued 97,339            
Old AEON Common Stock              
Class of Stock [Line Items]              
Maximum contingent consideration shares issuable 222,653